Raymond James & Associates Lexicon Pharmaceuticals, Inc. Call Options Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LXRX
# of Institutions
141Shares Held
238MCall Options Held
459KPut Options Held
133K-
Artal Group S.A. Luxembourg, N4136MShares$103 Million100.0% of portfolio
-
Siren, L.L.C. New York, NY38.9MShares$29.6 Million3.05% of portfolio
-
Orbimed Advisors LLC San Diego, CA11MShares$8.38 Million0.41% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$7.52 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.09MShares$6.15 Million0.0% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $143M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...